Drug · CHEMBL989

FLUOCINOLONE ACETONIDE

7 sourcespipelines-2026-09-18-0.3.1

Cite this record

ConductScience Library. FLUOCINOLONE ACETONIDE. Drugs and targets, record CHEMBL989. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL989

On this page

Drug

Names and IDs as ChEMBL gives them, through Open Targets.

Name: FLUOCINOLONE ACETONIDE; ChEMBL
ChEMBL ID: CHEMBL989; ChEMBL
Type: Small molecule; ChEMBL
Brand names: Capex, Derma-smoothe/fs, Dermotic, Fluocet, Fluocinolone acetonide component of iluvien, Fluocinolone acetonide component of neo-synalar, Fluocinolone acetonide component of otovel, Fluocinolone acetonide component of tri-luma, Fluonid, Fluotrex, Fs shampoo, Iluvien, Retisert, Synalar, Synalar fte, Synalar-c, Synalar-hp, Synalar-n, Synandone, Yutiq; ChEMBL
Other names: Acetonide de fluocinolone, Acetonido de fluocinolona, Flucinolone acetonide, Fluocinolide (acetate), Fluocinolone, NSC-92339, Oto-synalar; ChEMBL
DrugBank: DB00591; DrugBank
InChIKey: FEBLZLNTKCEFIT-VSXGLTOVSA-N; ChEMBL
Open Targets' highest stage: Approval, for 11 of its 23 diseases, from ATC, DailyMed and TTD; Open Targets

Targets1

The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.

Target	Protein	Mechanism	Action	Gene in Genes
NR3C1	Glucocorticoid receptor	Glucocorticoid receptor agonist	AGONIST	https://conductscience.org/library/genes/2908

Source ChEMBL

Diseases23

The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Disease	Open Targets' stage	Stage reported by	Reports	Of them trials	Its drugs
uveitis	Approval	DailyMed	11	9	https://conductscience.org/library/drugs?q=MONDO_0020283
diabetic macular edema	Phase 3	ClinicalTrials.gov	8	8	https://conductscience.org/library/drugs?q=MONDO_0004728
freckles	Approval	DailyMed	7	6	https://conductscience.org/library/drugs?q=EFO_0003963
age-related macular degeneration	Phase 2	ClinicalTrials.gov	3	3	https://conductscience.org/library/drugs?q=MONDO_0005150
macular retinal edema	Approval	DailyMed	3	2	https://conductscience.org/library/drugs?q=MONDO_0003005
acute otitis externa	Phase 3	ClinicalTrials.gov	2	2	https://conductscience.org/library/drugs?q=MONDO_0001051
posterior uveitis	Phase 1	ClinicalTrials.gov	2	2	https://conductscience.org/library/drugs?q=MONDO_0006918
atrophic macular degeneration	Phase 2	ClinicalTrials.gov	1	1	https://conductscience.org/library/drugs?q=EFO_1001492
bacterial vaginosis	Phase 3	ClinicalTrials.gov	1	1	https://conductscience.org/library/drugs?q=MONDO_0005316
choroidal neovascularization	Phase 1	ClinicalTrials.gov	1	1	https://conductscience.org/library/drugs?q=MONDO_0810000

1 to 10 of 23Source Open Targets

See all 23 diseases

Trials58

Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs. 3 more rest on that reading alone and are shown because the trials' posted result groups or NLM's indexing of their papers name the drug.

Trial	Title	Phase	Participants	Results first posted	Named as	Linked by	Source
NCT00344968	Fluocinolone Acetonide Implant Compared to Sham Injection in Patients With Diabetic Macular Edema	Phase 3	956	2014-05-07	fluocinolone acetonide	Its name	ClinicalTrials.gov
NCT03196973	Efficacy and Safety of DF289 Plus DF277 Otic Solution in the Treatment of Acute Otitis Externa	Phase 3	493	2021-04-09	fluocinolone acetonide	Its name	ClinicalTrials.gov
NCT01395966	Clinical Study to Assess the Efficacy and Safety of DF289 Plus DF277 Otic Solution in the Treatment of Middle Ear Infections in Pediatric Patients	Phase 3	331	2015-10-22	ciprofloxacin plus fluocinolone acetonide, fluocinolone acetonide	Its name	ClinicalTrials.gov
NCT01404611	Efficacy and Safety of DF289 Plus DF277 Otic Solution in the Treatment of Middle Ear Infections in Pediatric Patients	Phase 3	331	2015-11-23	ciprofloxacin plus fluocinolone acetonide, fluocinolone acetonide	Its name	ClinicalTrials.gov
NCT00132691	Multicenter Uveitis Steroid Treatment (MUST) Trial	Phase 4	255	2012-07-30	fluocinolone acetonide	Its name	ClinicalTrials.gov
NCT02168478	Neo-Synalar Modified 48 Hour Patch Test	Phase 4	206	2015-12-11	neo-synalar	Open Targets' reading, confirmed by the trial's result groups	ClinicalTrials.gov
NCT01867164	A Study to Compare Efficacy and Safety of an Ovule Containing Terconazole, Clindamycin and Fluocinolone Versus an Ovule Containing Metronidazole, Nystatin and Fluocinolone in the Treatment of Secondary Vulvar/ or Vaginal Symptoms of Infectious Vaginitis/ and Infectious Vaginosis	Phase 3	160	2013-12-24	fluocinolone acetonide	Its name	ClinicalTrials.gov
NCT02746991	Safety and Efficacy Study of a FAI Insert in Subjects With Chronic Non-infectious Posterior Uveitis	Phase 3	153	2020-07-07	fluocinolone acetonide	Its name	ClinicalTrials.gov
NCT01694186	Safety and Efficacy of an Injectable Fluocinolone Acetonide Intravitreal Insert	Phase 3	129	2020-03-23	fluocinolone acetonide	Its name	ClinicalTrials.gov
NCT01304706	Fluocinolone Acetonide in Diabetic Macular Edema (FAME) Extension Study	Phase 3	120	2015-05-04	fluocinolone acetonide	Its name	ClinicalTrials.gov

1 to 10 of 58

See all 58 trials

Comparisons in its trials14

Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Flucinolone Acetonide Implant vs Systemic Therapy: serious adverse events	75 of 129	47 of 126	255	NCT00132691	Trial comparisons
Gynoclin V (Terconazole+Clindamycin+Fluocinolone Acetonide) vs Vagitrol V (Metronidazole+Fluocinolone Acetonide+Nystatin): serious adverse events	0 of 81	0 of 79	160	NCT01867164	Trial comparisons
FAI Insert vs Sham Injection: Number of Participants With Recurrence of Uveitis in Study Eye Within 36 Months	47 of 101	39 of 52	153	NCT02746991	Trial comparisons
FAI Insert vs Sham Injection: Number of Participants With Recurrence of Uveitis in Study Eye Within 6 Months	22 of 101	28 of 52	153	NCT02746991	Trial comparisons
FAI Insert vs Sham Injection: deaths from any cause	0 of 101	0 of 52	153	NCT02746991	Trial comparisons
FAI Insert vs Sham Injection: serious adverse events	21 of 101	7 of 52	153	NCT02746991	Trial comparisons
FAI Insert vs Sham Injection: deaths from any cause	1 of 87	0 of 42	129	NCT01694186	Trial comparisons
FAI Insert vs Sham Injection: serious adverse events	29 of 87	17 of 42	129	NCT01694186	Trial comparisons
Intense Pulsed Light (IPL) / Tri-Luma® Cream vs Intense Pulsed Light (IPL) / Inactive Control Cream: Number of Participants With Tolerability Assessments Resulting in Adverse Events	1 of 56	0 of 56	112	NCT00669071	Trial comparisons
Fluocinolone Acetonide: 0.2 ug/Day Implant vs Fluocinolone Acetonide: 0.5 ug/Day Implant: serious adverse events	19 of 20	12 of 17	37	NCT00490815	Trial comparisons

1 to 10 of 14

See all 14 comparisons in its trials

Papers from its trials36

The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
39369111	RESULT	1	PubMed
38896402	RESULT	1	PubMed
38192412	RESULT	1	PubMed
35357753	RESULT	1	PubMed
33849384	RESULT	1	PubMed
32649234	RESULT	1	PubMed
31502392	RESULT	1	PubMed
31354327	RESULT	1	PubMed
25396122	RESULT	1	PubMed
25184917	RESULT	1	PubMed

1 to 10 of 36

See all 36 papers from its trials

Tests in its trials0

The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.

None in this release.

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
ClinicalTrials.gov: 2026-11-05; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
Papers the trials list, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
Tests named in the trials, as ScienceGraph matched them: 2026-11-12; ConductCognition

Sources 7

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ConductCognition's list of its testsOur own data
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this drug from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/drugs/v1/CHEMBL989

GET https://conductscience.org/api/drugs/v1/CHEMBL989/diseases?page=2

API reference For AI assistants